Skip to main content

Table 1 C. parapsilosis strains information, antifungal susceptibilities, microsatellite typing results and the MRR1 gene mutations

From: Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy

Strain no.a Patient Wardb Susceptibility results by Sensititre YeastOnec (μg/mL) Multilocus genotyped Genotypee MRR1
FLC VRC ITC POS ANF MCF CAS 5FC AMB B5 CP1 CP4 CP6
PU017 1 EGW 2 0.03 0.12 0.06 0.5 0.5 0.25 0.06 0.5 109/109 242/242 307/307 291/291 A T2957C/WT
PU110 1 EGW 2 0.03 0.12 0.06 0.5 0.5 0.25 0.06 0.5 109/109 242/242 307/307 291/291 A T2957C/WT
PU112 1 EGW 2 0.03 0.06 0.06 0.25 0.25 0.25 0.06 0.5 109/109 242/242 307/307 291/291 A T2957C/WT
PU116 1 EGW 2 0.03 0.06 0.06 0.5 0.5 0.25 0.06 0.5 109/109 242/242 307/307 291/291 A T2957C/WT
PU123 1 EGW 32 0.5 0.12 0.06 0.5 0.5 0.5 0.06 0.5 109/109 242/242 307/307 291/291 A T2957C/T2957C
PU127 1 EGW 32 0.5 0.12 0.06 0.5 0.5 0.5 0.06 0.5 109/109 242/242 307/307 291/291 A T2957C/T2957C
PU004 2 Outpatient 0.5 ≤0.008 0.06 0.03 0.5 0.5 0.25 0.06 0.5 107/107 242/242 307/307 267/267 B WT/WT
PU026 3 ICU 0.25 ≤0.008 0.03 0.03 0.5 0.5 0.25 0.06 0.5 143/145 242/242 304/304 282/282 C WT/WT
PU090 4 Medical ward 0.5 ≤0.008 0.03 0.03 0.5 0.5 0.25 ≤0.06 0.5 113/129 224/245 358/358 267/270 D WT/WT
PU106 5 Surgical ward 0.5 ≤0.008 0.06 0.03 0.5 0.25 0.12 0.06 0.5 109/109 242/242 307/307 291/291 Af WT/WT
PU108 6 EGW 0.5 ≤0.008 0.06 0.03 0.5 0.5 0.25 0.12 0.5 115/129 242/248 364/385 267/267 E WT/WT
PU131 7 Medical ward 0.5 ≤0.008 0.03 0.015 0.5 0.5 0.25 0.12 0.5 109/109 242/242 307/307 288/288 F WT/WT
ATCC 22019 - - 1 0.015 0.12 0.03 0.5 0.5 0.25 0.12 0.5 129/129 245/251 304/304 291/291 G WT/WT
  1. aAll strains were isolated from blood cultures
  2. bEGW Emergency general ward
  3. cFLC Fluconazole, VRC Voriconazole, ITC Itraconazole, POS Posaconazole, ANF Anidulafungin, MCF, Micafungin, CAS Caspofungin, 5FC 5-Flucytosine, AMB Amphotericin B. Clinical breakpoints for susceptible, intermediate, and resistant for C. parapsilosis, respectively, were those of the CLSI M27-S4 for fluconazole (≤2/4/ ≥8 μg/mL); and for voriconazole (≤0.125/0.25/≥1 μg/mL); and for anidulafungin, caspofungin, and micafungin (≤2/4/≥8 μg/mL)
  4. dThe numbers indicate the fragment size in base pairs of the different alleles obtained with the listed marker
  5. eThe genotype was designated according to the different microsatellite typing results
  6. fThe PU106 isolate yielded identical genotype with the isolates from patient 1